Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026)
Powered by 
Analysis
Tandem Diabetes Care (TNDM) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.84 Bn | 174.23 Bn | 7.27 Bn | 17.83% |
| 2 | Intuitive Surgical | 128.02 Bn | 122.81 Bn | 1.96 Bn | -26.99% |
| 3 | Medtronic | 117.28 Bn | 108.46 Bn | 6.34 Bn | -44.28% |
| 4 | Stryker | 103.92 Bn | 100.44 Bn | 4.50 Bn | -6.23% |
| 5 | Boston Scientific | 63.51 Bn | 62.97 Bn | 3.85 Bn | -32.54% |
| 6 | Edwards Lifesciences | 49.96 Bn | 45.70 Bn | 1.35 Bn | -68.12% |
| 7 | Alcon | 32.86 Bn | 31.40 Bn | 1.68 Bn | 18.69% |
| 8 | Dexcom | 32.25 Bn | 30.30 Bn | 830.00 Mn | 37.39% |
| 9 | Steris | 20.74 Bn | 20.26 Bn | 684.20 Mn | -17.67% |
| 10 | Tandem Diabetes Care | 1.26 Bn | 808.29 Mn | 144.78 Mn | -158.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -158.77% |
| Mar 31, 2026 | -95.07% |
| Dec 31, 2025 | -34.23% |
| Sep 30, 2025 | 51.10% |
| Jun 30, 2025 | 109.11% |
| Mar 31, 2025 | 20.91% |
| Dec 31, 2024 | 27.35% |
| Sep 30, 2024 | 20.23% |
| Jun 30, 2024 | 62.05% |
| Mar 31, 2024 | 6.03% |
| Dec 31, 2023 | 34.72% |
| Sep 30, 2023 | 29.39% |
| Jun 30, 2023 | 26.90% |
| Mar 31, 2023 | -40.94% |
| Dec 31, 2022 | 54.83% |
| Sep 30, 2022 | 13.88% |
| Jun 30, 2022 | 34.51% |
| Mar 31, 2022 | 88.33% |
| Dec 31, 2021 | -126.73% |
| Sep 30, 2021 | 5.74% |